 SAN CLEMENTE, Calif.--BUSINESS WIRE--Glaukos Corporation NYSE: GKOS, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. Santen for the PRESERFLOTM MicroShunt development code: DE-128, superseding the previous collaboration and distribution agreement 